Atreca Inc
F:0C1
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
N/A
N/A
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
A
|
Atreca Inc
F:0C1
|
1.7m EUR |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
385.9B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
187.6B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
163.7B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
119.4B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.7B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
86.4B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
42.7B EUR |
Loading...
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
48.8B USD |
Loading...
|
Market Distribution
Other Profitability Ratios
Atreca Inc
Glance View
Atreca, Inc. is a biopharmaceutical company. The company is headquartered in San Carlos, California and currently employs 134 full-time employees. The company went IPO on 2019-06-20. The firm use its platform to discover and develop antibody-based immunotherapeutic to treat a range of solid tumor types. The firm's lead product candidate, ATRC-101, is a monoclonal antibody with a mechanism of action and target derived from an antibody identified using its discovery platform. Its platform enables it to interrogate an active B cell response within an individual cancer patient to identify antibody-target pairs, which enable them to develop antibody-based product candidates to treat patients with solid tumors. ATRC-101 reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal and breast cancer samples from multiple patients. APN-122597 is its other product candidate. The firm's Immune Repertoire Capture (IRC) technology generates natively paired heavy and light chain sequences of the antibodies expressed by single B cells isolated from patient samples.